Changes in Determining Medicines Pricing in France, Germany and the UK

New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz summarised changes implemented or being discussed in pricing and reimbursement/HTA systems in France, Germany and the UK.

New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz summarised changes implemented or being discussed in pricing and reimbursement/HTA systems in France, Germany and the UK. In Germany and France, the emphasis of the recent reforms is centred around evidence requirements and, in particular, the choice of comparators and the use of head-to-head trials. In the UK, however, value-based pricing (VBP) is about the weighting given to the evidence and the social value of a drug. Overall, emphasis is increasing on “proving” innovation and/or an additional health benefit for a new medicine as a precondition for a price higher than existing competitors.

Jorge’s presentation was reported in El Global. Click here to read the article.